within Pharmacolibrary.Drugs.ATC.S;

model S01EC54
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EC54</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Brinzolamide is a carbonic anhydrase inhibitor used primarily for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma. In fixed combinations (such as with timolol), it offers enhanced efficacy for lowering eye pressure. It is approved and widely used in ophthalmology today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult patients; no specific published population PK modeling data for brinzolamide combinations (S01EC54) were identified.</p><h4>References</h4><ol><li><p>Iester, M (2008). Brinzolamide. <i>Expert opinion on pharmacotherapy</i> 9(4) 653–662. DOI:<a href=&quot;https://doi.org/10.1517/14656566.9.4.653&quot;>10.1517/14656566.9.4.653</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18312166/&quot;>https://pubmed.ncbi.nlm.nih.gov/18312166</a></p></li><li><p>Suzuki, G, et al., &amp; Kawamura, A (2021). Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations. <i>Current eye research</i> 46(3) 380–386. DOI:<a href=&quot;https://doi.org/10.1080/02713683.2020.1800046&quot;>10.1080/02713683.2020.1800046</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32706598/&quot;>https://pubmed.ncbi.nlm.nih.gov/32706598</a></p></li><li><p>Cvetkovic, RS, &amp; Perry, CM (2003). Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. <i>Drugs &amp; aging</i> 20(12) 919–947. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200320120-00008&quot;>10.2165/00002512-200320120-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14565787/&quot;>https://pubmed.ncbi.nlm.nih.gov/14565787</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EC54;
